Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) — Medicare Part D spending
Eli Lilly & Co. · Rank #82 by total Part D spend · CMS data year 2023
Medicare Part D spent $647,548,319 on Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) in 2023, the #82 drug by total Part D spending out of 3,598 drugs. That worked out to about $23.18 per dosage unit, $421 per claim and $1,839 per beneficiary, across 1,538,057 claims for 352,073 beneficiaries. Average spending per dosage unit rose +1.6% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) spending at a glance (2023)
| Metric | Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) |
|---|---|
| Total Part D spending (2023) | $647,548,319 |
| Total spending (2022) | $706,582,384 |
| Year-over-year change in total spending | -8.4% |
| Average spending per dosage unit (2023) | $23.18 |
| Change in spend per dosage unit (YoY) | +1.6% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +1.4% |
| Average spending per claim (2023) | $421 |
| Average spending per beneficiary (2023) | $1,839 |
| Total claims (2023) | 1,538,057 |
| Beneficiaries (2023) | 352,073 |
| Total dosage units (2023) | 27,938,494 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #82 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $706,582,384 | $647,548,319 | -8.4% |
| Avg spend per dosage unit | $22.82 | $23.18 | +1.6% |
| Avg spend per claim | $415 | $421 | — |
| Avg spend per beneficiary | $1,861 | $1,839 | — |
| Total claims | 1,701,833 | 1,538,057 | — |
| Beneficiaries | 379,615 | 352,073 | — |
How Basaglar Kwikpen U-100 compares with nearby drugs
Drugs with total Part D spending closest to Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) (this drug, #82) | $647,548,319 | $23.18 | +1.6% |
| Gabapentin (#80) | $655,916,853 | $0.15 | -6.8% |
| Levothyroxine Sodium* (Levothyroxine Sodium) (#81) | $653,594,902 | $0.25 | -10.2% |
| Abilify Maintena (Aripiprazole) (#83) | $636,857,891 | $2,732.27 | +7.0% |
| Dupixent Syringe (Dupilumab) (#84) | $633,292,043 | $966.09 | +6.7% |
| Triumeq (Abacavir/Dolutegravir/Lamivudi) (#85) | $631,607,443 | $123.90 | +6.8% |
Frequently asked questions
How much does Medicare Part D spend on Basaglar Kwikpen U-100?
Medicare Part D spent $647,548,319 on Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) in 2023 (the latest CMS data year), across 1,538,057 claims for 352,073 beneficiaries. That ranks #82 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Basaglar Kwikpen U-100?
In 2023, the weighted average Medicare Part D spending per dosage unit for Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) was $23.18. Compared with 2022 it rose +1.6%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Basaglar Kwikpen U-100?
CMS attributes Basaglar Kwikpen U-100 (Insulin Glargine,Hum.Rec.Anlog) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $421 and per beneficiary $1,839.
Is the Basaglar Kwikpen U-100 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20